China insulin aspart market 2018

50 %
50 %
Information about China insulin aspart market 2018
Business & Mgmt

Published on March 10, 2014

Author: fareeqrahal

Source: slideshare.net

Description

The collection of ‘Life Sciences’ market research reports has a new addition of “Investigation Report on China Insulin Aspart Market, 2009-2018”On chinamarketresearchreports.com . According to IDF (the International Diabetes Federation), incidence of diabetes among adults aged 2079 in the world was 8.3% in 2013 with more than 380 million patients worldwide.
On December 26, 2001 Novo Nordisk announced that the first insulin analogue insulin aspart (marketed by Novo Nordisk with the trade name "Novorapid") to treat insulin pump was approved by FDA. Insulin aspart was created through recombinant DNA technology so that the amino acid, B28, which is normally proline, is substituted with an aspartic acid residue. The sequence was inserted into the yeast genome, and the yeast expressed the insulin analog, which was then harvested from a bioreactor. This analog has increased charge repulsion, which prevents the formation of hexamers, to create fasteracting insulin. Insulin aspart can reduce the level of postprandial glucose and glycated hemoglobin A (HbA1c). The onset of action is approximately 10 to 20 minutes. The global sales revenue of Novorapid in 2012 reached USD 2.78 billion, increased by 20% YOY. In April 2005, the first premixed insulin analogue Novomix 30 (composed of 30% soluble insulin aspart and 70% insulin aspart protamine) was launched in China.

Investigation Report on China Insulin Aspart Market, 2009-2018 by China Research and Intelligence Explore all reports for “Life Sciences” market @ http://www.chinamarketresearchreports.com/cat/li fe-sciences.html. © ChinaMarketResearchReports.com ; sales@chinamarketresearchreports.com ; +1 888 391 5441

Investigation Report on China Insulin Aspart Market, 2009-2018 The collection of ‘Life Sciences’ market research reports has a new addition of “Investigation Report on China Insulin Aspart Market, 2009-2018”On chinamarketresearchreports.com . According to IDF (the International Diabetes Federation), incidence of diabetes among adults aged 2079 in the world was 8.3% in 2013 with more than 380 million patients worldwide. On December 26, 2001 Novo Nordisk announced that the first insulin analogue insulin aspart (marketed by Novo Nordisk with the trade name "Novorapid") to treat insulin pump was approved by FDA. Insulin aspart was created through recombinant DNA technology so that the amino acid, B28, which is normally proline, is substituted with an aspartic acid residue. The sequence was inserted into the yeast genome, and the yeast expressed the insulin analog, which was then harvested from a bioreactor. This analog has increased charge repulsion, which prevents the formation of hexamers, to create fasteracting insulin. Insulin aspart can reduce the level of postprandial glucose and glycated hemoglobin A (HbA1c). The onset of action is approximately 10 to 20 minutes. The global sales revenue of Novorapid in 2012 reached USD 2.78 billion, increased by 20% YOY. In April 2005, the first premixed insulin analogue Novomix 30 (composed of 30% soluble insulin aspart and 70% insulin aspart protamine) was launched in China. Inquire for a discount on this report @ http://www.chinamarketresearchreports.com/contacts/inquiry.php?name=114 745 . © ChinaMarketResearchReports.com ; sales@chinamarketresearchreports.com ; +1 888 391 5441

Investigation Report on China Insulin Aspart Market, 2009-2018 Rapid economic growth in the last 30 years has changed Chinese people's eating habits and led to less physical activities. Incidence of diseases related to obesity keeps increasing. In China 40% of the youth aged 1829 are potential diabetes patients with a higher risk of stroke, heart disease and renal failure. By the end of 2013 there were about 98 to 120 million diabetes patients in China. The market size of diabetes drugs is also increasing. According to CRI's investigation on certain Chinese sample hospital market, the sales revenue of insulin aspart increased over 100 times from 2005 to 2013. Insulin aspart market in China is seized by Novo Nordisk. CRI's investigation also states that some Chinese enterprises are applying for production of the generic drug, which is expected to appear on the market no sooner than 2015. The number of diabetes patients as well as the market size of insulin aspart in China is predicted to increase in the next few years. Complete report available @ http://www.chinamarketresearchreports.com/114745.html . © ChinaMarketResearchReports.com ; sales@chinamarketresearchreports.com ; +1 888 391 5441

Add a comment

Related presentations

Canvas Prints at Affordable Prices make you smile.Visit http://www.shopcanvasprint...

30 Días en Bici en Gijón organiza un recorrido por los comercios históricos de la ...

Con el fin de conocer mejor el rol que juega internet en el proceso de compra en E...

With three established projects across the country and seven more in the pipeline,...

Retailing is not a rocket science, neither it's walk-in-the-park. In this presenta...

What is research??

What is research??

April 2, 2014

Explanatory definitions of research in depth...

Related pages

Investigation Report on China Insulin Aspart Market, 2009-2018

Table of Contents. 1 Relevant Concepts of Insulin Aspart 1.1 Development Process and Indication 1.2 Sales Status on the Global Market. 2 Market Overview of ...
Read more

China Insulin Aspart & Lispro Market Investigation Reports ...

China Insulin Aspart & Lispro Market Investigation Reports Forecast to 2018 Now Available at ChinaMarketResearchReports.com
Read more

Investigation report on china insulin aspart market, 2009 2018

User profile menu Publisher Home Feed Explore. Profile Stacks Following Account Settings Premium Features
Read more

China Insulin Aspart Market 2018 | Healthcare

(Before It's News) The report “Investigation Report on China Insulin Aspart Market, 2009-2018″ by China Research and Intelligence is now ...
Read more

Research and Forecast on China Insulin Market, 2014-2018

Insulin Markets in China published: Apr 1, 2016 Japan Diabetes Market Report: Patients, Prevalence, Oral Antidiabetics, Insulin and Diagnostics published ...
Read more

China Insulin Market Trends, Growth and Forecast up to ...

Title: China Insulin Market Trends, ... Research and Forecast on China Insulin Market, 2014-2018 carries on a thorough analysis of development history, ...
Read more

China Insulin Market, 2014 - 2018 | NILESH KINDARLE | LinkedIn

China’s insulin market scale approximately registered CNY 11 billion in 2013, ... China Insulin Market, 2014 - 2018 NILESH KINDARLE.
Read more

Research and Forecast on China Insulin Market, 2014-2018 ...

... (insulin aspart and insulin lispro) ... Environment of China Insulin Market in 2013 ... Trend and Prospect Forecast of China Insulin Market, 2014-2018
Read more

Research and Forecast on China Insulin Market, 2014 - 2018 ...

Research and Forecast on China Insulin Market, 2014-2018 carries on a ... shows that China’s insulin market scale ... aspart and insulin ...
Read more